Cargando…

Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE

Background The noninterventional XALIA study compared rivaroxaban with standard anticoagulation for deep vein thrombosis treatment. This substudy describes the demographics, clinical characteristics, and outcomes of the patients with cancer. Methods Therapy type, dose, and duration were at the phy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ageno, Walter, Mantovani, Lorenzo G., Haas, Sylvia, Kreutz, Reinhold, Monje, Danja, Schneider, Jonas, van Eickels, Martin, Gebel, Martin, Turpie, Alexander G. G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2017
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598195/ https://www.ncbi.nlm.nih.gov/pubmed/31259294 http://dx.doi.org/10.1055/s-0037-1603924

Ejemplares similares

Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA‐LEA noninterventional studies
por: Haas, Sylvia, et al.
Publicado: (2021)

Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis
por: Cano, Stefan, et al.
Publicado: (2018)

Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIA
por: Ageno, Walter, et al.
Publicado: (2019)

XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis
por: Ageno, Walter, et al.
Publicado: (2014)

Predictive value of venous thromboembolism (VTE)‐BLEED to predict major bleeding and other adverse events in a practice‐based cohort of patients with VTE: results of the XALIA study
por: Klok, Frederikus A., et al.
Publicado: (2018)

Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery
por: Turpie, Alexander GG, et al.
Publicado: (2012)

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation
por: Camm, A John, et al.
Publicado: (2014)

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Characteristics and Effect of Rivaroxaban on Venous Thromboembolism in Korean Patients Compared to Western Population: A Subgroup Analysis from XALIA(-LEA) Study
por: Min, Seung-Kee, et al.
Publicado: (2022)

Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co‐medication interactions
por: Kreutz, Reinhold, et al.
Publicado: (2016)

XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation
por: Camm, A. John, et al.
Publicado: (2016)

Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE
por: Ageno, Walter, et al.
Publicado: (2021)

On-treatment Comparative Effectiveness of Vitamin K Antagonists and Direct Oral Anticoagulants in GARFIELD-VTE, and Focus on Cancer and Renal Disease
por: Haas, Sylvia, et al.
Publicado: (2022)

Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism
por: Turpie, Alexander G.G.
Publicado: (2012)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
por: Turpie, Alexander GG
Publicado: (2014)

Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE
por: Jerjes-Sánchez, Carlos, et al.
Publicado: (2021)

Comparative Assessment of the Anticoagulant Activity of Rivaroxaban and Dabigatran in Patients With Nonvalvular Atrial Fibrillation: A Noninterventional Study
por: Tsantes, Argirios E., et al.
Publicado: (2016)

The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery – subgroup analyses from 17,701 patients in the XAMOS study
por: Haas, Sylvia, et al.
Publicado: (2016)

Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD‐VTE
por: Cohen, Omri, et al.
Publicado: (2021)

Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk
por: Haas, Sylvia, et al.
Publicado: (2014)

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
por: Beyer-Westendorf, Jan, et al.
Publicado: (2019)

Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review
por: van der Wall, Sake J., et al.
Publicado: (2018)

Menstruation, anticoagulation, and contraception: VTE and uterine bleeding
por: Samuelson Bannow, Bethany, et al.
Publicado: (2021)

Extended anticoagulation for VTE: what evidence justifies it?
por: Walia, Anushka, et al.
Publicado: (2023)

Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real‐world prospective study
por: Camm, A. John, et al.
Publicado: (2020)

Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy
por: Wells, Philip S, et al.
Publicado: (2014)

Duration of anticoagulant therapy and VTE recurrence in patients with cancer
por: Khorana, Alok A., et al.
Publicado: (2019)

Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients
por: Kwong, Louis, et al.
Publicado: (2015)

Blood Being Tricky: Anticoagulation-Resistant Venous Thromboembolism (VTE)
por: Tiperneni, Raghu, et al.
Publicado: (2022)

Comparative Effectiveness of Apixaban and Rivaroxaban Lead-in Dosing in VTE Treatment: Observational Multicenter Real-World Study
por: Alshaya, Omar A., et al.
Publicado: (2022)

Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
por: Burnett, Allison E., et al.
Publicado: (2016)

Clinical significance of the rivaroxaban–dronedarone interaction: insights from physiologically based pharmacokinetic modelling
por: Hügl, Burkhard, et al.
Publicado: (2023)

Clot regression effects of rivaroxaban in the treatment of venous thromboembolism in patients with cancer (CRERIT-VTE cancer): study protocol
por: Takai, Shigeki, et al.
Publicado: (2019)

Risk of Bleeding Associated With Outpatient Use of Rivaroxaban in VTE Management at a National Referral Hospital in Western Kenya
por: Njuguna, Dennis, et al.
Publicado: (2023)

Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry
por: Ohsumi, Shozo, et al.
Publicado: (2023)

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
por: de Winter, Maria A, et al.
Publicado: (2023)

Comparison of VTE risk scores in guidelines for VTE diagnosis in nonsurgical hospitalized patients with suspected VTE
por: Xiong, Wei, et al.
Publicado: (2023)

Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms
por: Huenerbein, Karlo, et al.
Publicado: (2020)

Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban
por: Eikelboom, John W., et al.
Publicado: (2015)

Leukocytoclastic Vasculitis Associated with a New Anticoagulant: Rivaroxaban
por: Hasbal, Nuri Barış, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_okv93t24n0cm21k1r2i3dgec6p